A novel topical gel for treating migraines showed promise in a clinical trial: 77% of patients experienced pain relief. Advantages of the new transdermal approach include delivery directly to the affected nerves and tissue. By bypassing the digestive system, the drug avoids systematic circulation in the body. This limits side effects and enables fast action. North Carolina's Achelios Therapeutics says its formulation facilitates superior penetrations of the active ingredient (an over-the-counter, anti-inflammatory molecule called ketoprofen) through the skin, for overcoming the dermal barrier has been a challenge for other topical treatments. Dubbed Topofen, the candidate is ready for Phase IIb trials. More about the trial (reg. req.) | Here's more info about Achelios